Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents

D. C. Calverley, G. J. Roth

    Research output: Contribution to journalArticlepeer-review

    13 Scopus citations


    Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

    Original languageEnglish (US)
    Pages (from-to)1231-1249
    Number of pages19
    JournalHematology/Oncology Clinics of North America
    Issue number6
    StatePublished - 1998

    ASJC Scopus subject areas

    • Hematology
    • Oncology


    Dive into the research topics of 'Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents'. Together they form a unique fingerprint.

    Cite this